Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pellets

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Pellets. Displaying page 1 of 1.
    EudraCT Number: 2004-001218-15 Sponsor Protocol Number: SAG-27/UCR Start Date*: 2005-04-04
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomised, multicentre, 12-months, comparative study of the efficacy and tolerability of once daily 3.0 g mesalazine granules versus once daily 1.5 g mesalazine granule...
    Medical condition: Maintenance therapy of ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) SK (Completed) HU (Completed) EE (Completed) LV (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2004-001216-31 Sponsor Protocol Number: SAG-26/UCA Start Date*: 2005-05-30
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomised, multicentre, comparative study of the efficacy and tolerability of once daily 3.0 g mesalazine granules versus three times daily 1.0 g mesalazine granules in...
    Medical condition: Therapy of active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058816 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) SK (Completed) HU (Completed) LV (Completed) CZ (Completed) EE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2008-007952-90 Sponsor Protocol Number: LT-02-UC-01 Start Date*: 2009-11-17
    Sponsor Name:Lipid Therapeutics GmbH
    Full Title: A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulce...
    Medical condition: Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) ≥5 and SCCAI subscore for “blood in sto...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003955-13 Sponsor Protocol Number: MK-1439-066 Start Date*: 2020-06-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine in Participants With HIV-1 Aged 4 Weeks to <12 Years of Age and Weighing <35 kg
    Medical condition: Pediatric HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-009377-10 Sponsor Protocol Number: NAL-OIC-01 Start Date*: 2009-05-27
    Sponsor Name:SLA Pharma (UK) Ltd
    Full Title: A Multicenter, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Efficacy Study of Naloxone SR capsules in Subjects with Constipation due to Opioids ta...
    Medical condition: Opioid Induced Constipation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021175 Iatrogenic constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002114-12 Sponsor Protocol Number: 1160.106 Start Date*: 2013-09-20
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: Open-label, randomized, parallel-group, active-controlled, multi-centre, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) BE (Completed) ES (Completed) SE (Completed) FI (Completed) SK (Completed) GR (Completed) NO (Completed) IT (Completed) AT (Completed) BG (Completed) Outside EU/EEA FR (Completed) HU (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005982-18 Sponsor Protocol Number: COQ10-FM-2012 Start Date*: 2013-01-09
    Sponsor Name:Mónica Saldaña Valderas
    Full Title: Randomized, placebo-controlled and double blind clinical trial to assess the efficacy of ubidecarenone in patients diagnosed with fibromyalgia
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005032-42 Sponsor Protocol Number: 17-162 Start Date*: 2020-04-20
    Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty
    Full Title: Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease
    Medical condition: Diabetes Type 2 with existing cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000099-17 Sponsor Protocol Number: AGO/2007/001 Start Date*: 2007-02-13
    Sponsor Name:University Hospital Gent
    Full Title: Farmacokinetische evaluatie van enteraal toegediende omeprazole-suspensie bij patiënten met cerebral palsy.
    Medical condition: gastro-oesophagale reflux
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017924 Gastroesophageal reflux LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004769-41 Sponsor Protocol Number: 7572 Start Date*: 2020-02-18
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: Prospective randomized versus placebo study evaluating the feasibility of plasma therapy in septic shock induced coagulopathy
    Medical condition: Septic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000854-30 Sponsor Protocol Number: 3200K1-4000-WW(B2541005) Start Date*: 2009-02-27
    Sponsor Name:Salix Pharmaceuticals Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Addition...
    Medical condition: Opioid-induced constipation in subjects with advanced illness
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Completed) FI (Prematurely Ended) DK (Prematurely Ended) PT (Completed) SE (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004844-23 Sponsor Protocol Number: 20101299 Start Date*: 2012-06-12
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012444-16 Sponsor Protocol Number: 39758979ASH2001 Start Date*: 2009-09-25
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Exploratory Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults with Persistent Asthma
    Medical condition: JNJ-39756979 is being developed for the treatment of asthma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004845-42 Sponsor Protocol Number: 20110165 Start Date*: 2012-05-30
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005153-32 Sponsor Protocol Number: HGS1012-C1072 Start Date*: 2008-03-26
    Sponsor Name:Human Genome Sciences Inc.
    Full Title: A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAPATUMUMAB ( [HGS1012], A FULLY HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH CARBOPLATIN ...
    Medical condition: Advanced Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-004651-23 Sponsor Protocol Number: IJB-SYNERGY-012017 Start Date*: 2018-10-16
    Sponsor Name:Institut Jules Bordet
    Full Title: A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative ...
    Medical condition: Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003091-14 Sponsor Protocol Number: AB-106-G208 Start Date*: 2022-06-09
    Sponsor Name:AnHeart Therapeutics Inc
    Full Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005269-15 Sponsor Protocol Number: CO42865 Start Date*: 2022-05-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER
    Medical condition: RET-mutated Medullary Thyroid Cancer (MTC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) BG (Completed) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 18:34:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA